All News

Uroplasty announced that Humana, Inc. has written a positive coverage policy for percutaneous tibial nerve stimulation delivered via its Urgent PC Neuromodulation System.

Men with short-ended chromosomes in the immune cells in their blood appear to be at increased risk for aggressive prostate cancer compared with men with long-ended chromosomes, according to findings from a recent study.

A study of several hundred chemicals used in commercial pesticides has found only weak evidence that any of them are associated with hypospadias, the authors reported.

Much of what is said by critics of the RUC process is at best incorrect and at worst purposely misstated.

The FDA has approved a product label addition for the phosphodiesterase-type-5 inhibitor tadalafil (Cialis) that involves its use with finasteride (Proscar).

Urology drugs and devices in the pipeline from AltheRx Pharmaceuticals, TARIS Biomedical, AstraZeneca, NxThera, NovaBay Pharmaceuticals, and OncoGenex Pharmaceuticals.

Energized by recent legislative victories from Tallahassee to Olympia, urologists looked to the future as they gathered for the 6th annual AACU State Society Network Advocacy Conference. Taking place just days after the Oct. 1 launch of open enrollment for health insurance exchange plans, the event focused on the role of urologists and their professional associations in a transformed health care delivery system.

The latest products and services from SuperSonic Imagine, Auxilium Pharmaceuticals, VIVUS, the Centers for Medicare & Medicaid Services, Innovus Pharmaceuticals, Buffalo Filter, KRS Global Biotechnology, Demos Health, and Ethicon Endo-Surgery.

A phase III trial of enzalutamide (Xtandi) in chemotherapy-naïve patients with advanced prostate cancer has met both of its primary endpoints in an interim analysis, and the trial will be stopped early due to the drug’s benefit.

The 2013 Arthur D. Smith Endourology Lectureship has been awarded to Thomas Knoll, MD, of University Medical Center Mannheim and the Sindelfingen Medical Center of the University of Tuebingen, Germany.

The AUA said it will launch a national, specialty-wide urologic registry designed to measure and report health care quality and patient outcomes as well as provide data to help identify patterns and trends in the diagnosis and treatment of prostate cancer and eventual outcomes related to treatment options.

The publication of data in the New England Journal of Medicine (2013; 369:1629-37) showing an increase in intensity-modulated radiation therapy utilization among self-referring urologists has reignited the self-referral controversy.

Vitamin D does not appear to increase risk for developing kidney stones, say researchers from the University of California, San Diego.

Many physicians continue to administer the PSA test to even their oldest patients despite the fact that no medical organization recommends routine prostate cancer screening in men older than 75 years of age, according to recently published research.

Researchers at the Duke Cancer Institute in Durham, NC say they have developed a tool to forecast the potential survival of individual prostate cancer patients, enabling physicians to better assess whether to try additional rounds of treatment or seek clinical trials.

The first phase II study to investigate the use of the targeted therapy everolimus (Afinitor) for the initial treatment of advanced papillary kidney cancer has shown that it is successful in slowing or preventing the spread of the disease.

Women with common forms of urinary incontinence have various bacteria in their bladder, according to a recent study, and some of these bacteria may differ based on their incontinence type.

In this interview, Dr. Samir S. Taneja discusses the AUA's recommendations on the optimal method to perform a prostate biopsy and handle specimens as well as how to minimize infection and the role of imaging.

Results from a study in an experimental model of cystitis point to the cannabinoid receptor 2 (CB2) as a potential target to develop effective new therapies for patients with painful bladder disorders.

Urinary measurement of inflammatory chemokines may offer a noninvasive method for evaluating treatment response to sacral neuromodulation (InterStim Therapy, Medtronic, Inc., Minneapolis) in patients with interstitial cystitis/painful bladder syndrome, says Michael Chancellor, MD.

Thulium vapoenucleation of the prostate provided significant and durable symptomatic improvement in benign prostatic obstruction, long-term follow-up of a clinical series showed.

Primary androgen deprivation therapy for localized prostate cancer is associated with significantly better survival outcomes in a Japanese cohort compared with an American population, according to a recent study.

In many cases, you have the option of recouping revenue from previous practices/business structures that you no longer report, as long as you can provide the data.

Congratulations to Shlomo Raz, MD, who has been honored by the Confederation Americano de Urologia by naming its highest accolade in his honor and bestowing the first medal on him.

In this article, I examine and question the phenomenon of “the urine drop-off”-having the patient with suspected UTI collect a urine sample at home and drop it off at the practice-in the context of best clinical practice, common sense, and basic office efficiency.

Permanent insurance needs are met through varying types of whole life and universal life insurance policies designed to stay in force throughout one’s lifetime. Unlike term insurance, where premiums generally increase as the insured ages, most permanent life insurance premiums remain level.

"Do I think [ICD-10] will make patient care better? If it did, I would be really shocked. The question is, will it make patient care worse? I hope not.”

Single-fraction radiotherapy for bone metastases from prostate cancer is not widely used despite its comparable efficacy and lower cost in relation to multiple-fraction treatment, according to a recent study.